Advertisement

Resolvyx Pharmaceuticals Inc., a Bedford-based developer of anti-inflammatory drugs, and Celtic Pharma, based in the U.S. Virgin Islands, have entered into a deal relating to Resolvyx’s dry-eye syndrome treatment.

The agreement gives Celtic Pharma an exclusive option to acquire and license rights to RX-10045, the late-stage treatment for dry eye syndrome developed by Resolvyx. Celtic Pharma also has the option to license rights to another eye treatment.

SOURCE

Advertisement
Advertisement